Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anju Lele

Internal Medicine Mentor, OH Medical Doctor

NPI 1558467423 CMS profile 160889

9000 Mentor Ave Ste 105, Mentor, OH 44060

Open in the dashboard

General payments

$11,354

698 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anju Lele of Mentor, OH is reported in the CMS Open Payments database as having received $11,354 across 698 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,276 141
2024 General $2,469 135
2023 General $2,039 129
2022 General $579 30
2021 General $1,055 66
2020 General $993 62
2019 General $1,943 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anju Lele
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anju Lele were reported at $2,276. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anju Lele Internal Medicine median Middle half National median
2019 $1,943 $159 $48–$570 $163
2020 $993 $119 $33–$402 $114
2021 $1,055 $135 $37–$521 $132
2022 $579 $141 $42–$496 $149
2023 $2,039 $149 $45–$519 $160
2024 $2,469 $154 $47–$537 $164
2025 $2,276 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,065 65 payments
  2. Amgen Inc. $1,057 55 payments
  3. Novo Nordisk Inc $805 57 payments
  4. Pfizer Inc. $580 41 payments
  5. Merck Sharp & Dohme Corporation $547 33 payments
  6. GlaxoSmithKline, LLC. $517 35 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $494 31 payments
  8. AstraZeneca Pharmaceuticals LP $475 31 payments
  9. Lilly USA, LLC $464 42 payments
  10. Astellas Pharma US Inc $404 21 payments
  11. Other $4,946 287 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,354 698 payments
Products named General payments · program years 2019–2025
  1. Ozempic $611 44 payments
  2. UBRELVY $459 27 payments
  3. Repatha $451 21 payments
  4. RYBELSUS $448 34 payments
  5. EVENITY $444 24 payments
  6. Prolia $386 22 payments
  7. NURTEC ODT $362 26 payments
  8. TRELEGY ELLIPTA $356 26 payments
  9. Veozah $323 16 payments
  10. REXULTI $322 11 payments
  11. Other $11,286 726 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 149 drugs

Part D claims

11,501

Median for Internal Medicine: 777

Drug cost

$802,586

Median for Internal Medicine: $73,373

Branded share of claims

18.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 175 $135,063
Januvia Sitagliptin Phosphate Brand 87 $108,107
Xarelto Rivaroxaban Brand 70 $83,909
Ozempic Semaglutide Brand 45 $47,182
Mounjaro Tirzepatide Brand 42 $43,562
Farxiga Dapagliflozin Propanediol Brand 27 $30,437
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $20,292
Trulicity Dulaglutide Brand 21 $19,862
Vraylar Cariprazine Hcl Brand 17 $18,215
Symbicort Budesonide/Formoterol Fumarate Brand 44 $17,608

The 10 drugs with the highest cost, of 149 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$203,012

Of which drugs: $9,356

Medicare patients

526

Average age 75

Services billed

3,003

371 women, 155 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 34%
Ischemic heart disease 30%
Depression 29%
COPD 28%
Chronic kidney disease 27%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 20 20 $5,832
Vaccine for influenza for injection into muscle 90662 Office 52 52 $3,414

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $239
  • Otsuka America Pharmaceutical, Inc. $89
$328 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $118
  • PFIZER INC. $24
$142 175 —
UBRELVY
  • AbbVie, Inc. $128
$128 — —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $112
$112 — —
Veozah
  • Astellas Pharma US Inc $110
$110 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

698 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record